{"id":403054,"date":"2020-12-18T16:03:19","date_gmt":"2020-12-18T21:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403054"},"modified":"2020-12-18T16:03:19","modified_gmt":"2020-12-18T21:03:19","slug":"nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/","title":{"rendered":"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs"},"content":{"rendered":"

<\/p>\n

Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs<\/b><\/p>\n

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nRegulatory News:\n<\/p>\n

NANOBIOTIX<\/a> (Paris:NANO) (Euronext: NANO \u2013 Nasdaq: NBTX \u2013 the \u2018\u2018Company<\/b>\u2019\u2019), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the closing of an additional 1,095,000 American Depositary Shares (\u201cADSs<\/b>\u201d) pursuant to the full exercise of the underwriters\u2019 option to purchase additional ADSs in connection with the Company\u2019s initial public offering on the Nasdaq Global Select Market.\n<\/p>\n

\nThe 1,095,000 additional ADSs were sold at $13.50 per ADS, the same public offering price as in the initial public offering. Consequently, the total number of ordinary shares issued amounts to 8,395,000, including 6,540,000 in the form of ADSs, and the total net proceeds (including the sale of the additional ADSs pursuant to the exercise of the underwriters\u2019 option), after deducting underwriting commissions and estimated offering expenses payable by Nanobiotix, from the initial public offering were approximately $100.4 million (\u20ac82.8 million)1<\/sup>. The Company believes that the total net proceeds, together with its cash and cash equivalents, will be sufficient to fund its operations through the middle of the second quarter of 2023.\n<\/p>\n

\nNanobiotix’s ordinary shares are listed on the regulated market of Euronext in Paris under the ticker symbol “NANO”. Nanobiotix\u2019s ADSs began trading on the Nasdaq Global Select Market on December 11, 2020 under the ticker symbol “NBTX”.\n<\/p>\n

\nJefferies LLC acted as global coordinator and joint book-running manager for the global offering, and Evercore Group, L.L.C. and UBS Securities LLC acted as joint book-running managers for the U.S. offering. Gilbert Dupont acted as manager for the European offering.\n<\/p>\n

\nThe initial public offering was made only by means of a prospectus. A copy of the prospectus relating to the initial public offering was filed with the U.S. Securities and Exchange Commission and may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com<\/a>; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com<\/a>; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com<\/a>.\n<\/p>\n

Allocation of the Share Capital<\/b><\/p>\n

\nThe following table presents the expected allocation of the Company’s share capital following the initial public offering, to the Company\u2019s knowledge:\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

Situation before the capital increase (on a
\n
non-diluted basis)<\/b><\/p>\n<\/td>\n

\n

Situation after the capital increase (on a non-
\n
diluted basis and including the exercise of
\n
the underwriters\u2019 option to purchase
\n
additional ADSs )<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Shareholders<\/b><\/p>\n<\/td>\n

\n

Number of
\n
shares<\/b><\/p>\n<\/td>\n

\n

% of share
\n
capital<\/b><\/p>\n<\/td>\n

\n

% of voting
\n
rights <\/b><\/p>\n<\/td>\n

\n

Number of
\n
shares(1)<\/sup><\/b><\/p>\n<\/td>\n

\n

% of share
\n
capital<\/b><\/p>\n<\/td>\n

\n

% of voting
\n
rights <\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nInstitutional Investors\n<\/p>\n<\/td>\n

\n

\n8,428,377\n<\/p>\n<\/td>\n

\n

\n32.37%\n<\/p>\n<\/td>\n

\n

\n31.17%\n<\/p>\n<\/td>\n

\n

\n11,509,459\n<\/p>\n<\/td>\n

\n

\n33.43%\n<\/p>\n<\/td>\n

\n

\n32.48%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAmiral Gestion\n<\/p>\n<\/td>\n

\n

\n1,418,179\n<\/p>\n<\/td>\n

\n

\n5.45%\n<\/p>\n<\/td>\n

\n

\n5.25%\n<\/p>\n<\/td>\n

\n

\n1,479,619\n<\/p>\n<\/td>\n

\n

\n4.30%\n<\/p>\n<\/td>\n

\n

\n4.18%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nBaillie Gifford\n<\/p>\n<\/td>\n

\n

\n409,836\n<\/p>\n<\/td>\n

\n

\n1.57%\n<\/p>\n<\/td>\n

\n

\n1.52%\n<\/p>\n<\/td>\n

\n

\n2,109,836\n<\/p>\n<\/td>\n

\n

\n6.13%\n<\/p>\n<\/td>\n

\n

\n5.95%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nQatar Holding\n<\/p>\n<\/td>\n

\n

\n0\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n

\n

\n1,850,000\n<\/p>\n<\/td>\n

\n

\n5.37%\n<\/p>\n<\/td>\n

\n

\n5.22%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nInvus\n<\/p>\n<\/td>\n

\n

\n330,000\n<\/p>\n<\/td>\n

\n

\n1.27%\n<\/p>\n<\/td>\n

\n

\n1.22%\n<\/p>\n<\/td>\n

\n

\n2,032,478\n<\/p>\n<\/td>\n

\n

\n5.90%\n<\/p>\n<\/td>\n

\n

\n5.74%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRetail\n<\/p>\n<\/td>\n

\n

\n13,734,003\n<\/p>\n<\/td>\n

\n

\n52.75%\n<\/p>\n<\/td>\n

\n

\n50.80%\n<\/p>\n<\/td>\n

\n

\n13,734,003\n<\/p>\n<\/td>\n

\n

\n39.89%\n<\/p>\n<\/td>\n

\n

\n38.76%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nManagement\n<\/p>\n<\/td>\n

\n

\n962,613\n<\/p>\n<\/td>\n

\n

\n3.70%\n<\/p>\n<\/td>\n

\n

\n6.06%\n<\/p>\n<\/td>\n

\n

\n962,613\n<\/p>\n<\/td>\n

\n

\n2.80%\n<\/p>\n<\/td>\n

\n

\n4.62%\n<\/p>\n<\/td>\n<\/tr>\n

\n

including Laurent Levy<\/i><\/p>\n<\/td>\n

\n

809,060<\/i><\/p>\n<\/td>\n

\n

3.11%<\/i><\/p>\n<\/td>\n

\n

5.10%<\/i><\/p>\n<\/td>\n

\n

809,060 <\/i><\/p>\n<\/td>\n

\n

2.35%<\/i><\/p>\n<\/td>\n

\n

3.90%<\/i><\/p>\n<\/td>\n<\/tr>\n

\n

\nEmployees (excl.
\n
management)\n<\/p>\n<\/td>\n

\n

\n450,211\n<\/p>\n<\/td>\n

\n

\n1.73%\n<\/p>\n<\/td>\n

\n

\n2.87%\n<\/p>\n<\/td>\n

\n

\n450,211\n<\/p>\n<\/td>\n

\n

\n1.31%\n<\/p>\n<\/td>\n

\n

\n2.19%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nFamily offices and others\n<\/p>\n<\/td>\n

\n

\n298,388\n<\/p>\n<\/td>\n

\n

\n1.15%\n<\/p>\n<\/td>\n

\n

\n1.10%\n<\/p>\n<\/td>\n

\n

\n298,388\n<\/p>\n<\/td>\n

\n

\n0.87%\n<\/p>\n<\/td>\n

\n

\n0.84%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLiquidity Contract\n<\/p>\n<\/td>\n

\n

\n5,515\n<\/p>\n<\/td>\n

\n

\n0.02%\n<\/p>\n<\/td>\n

\n

\n0.02%\n<\/p>\n<\/td>\n

\n

\n5,515\n<\/p>\n<\/td>\n

\n

\n0.02%\n<\/p>\n<\/td>\n

\n

\n0.02%\n<\/p>\n<\/td>\n<\/tr>\n

\n

Total<\/b><\/p>\n<\/td>\n

\n

26,037,122<\/b><\/p>\n<\/td>\n

\n

100.00%<\/b><\/p>\n<\/td>\n

\n

100.00%<\/b><\/p>\n<\/td>\n

\n

34,432,122 <\/b><\/p>\n<\/td>\n

\n

100.00%<\/b><\/p>\n<\/td>\n

\n

100.00%<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(1) 6,540,000 of which are ordinary shares represented by ADSs<\/i><\/p>\n

\n***\n<\/p>\n

About NANOBIOTIX<\/b><\/p>\n

\nIncorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.\n<\/p>\n

\nThe Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.\n<\/p>\n

\nNanobiotix\u2019s novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix\u2019s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.\n<\/p>\n

\nNanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO \/ ISIN: FR0011341205 \/ Bloomberg: NANO: FP) and the Nasdaq Global Select Market (Nasdaq: NBTX). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.\n<\/p>\n

Disclaimer<\/b><\/p>\n

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. <\/i><\/p>\n

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions. <\/i><\/p>\n

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation. <\/i><\/p>\n

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.<\/i><\/p>\n

1<\/sup> Based on an exchange rate of \u20ac1.00 = $1.2115 as published by the European Central Bank on December 10, 2020.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201218005508\/en\/<\/a><\/span><\/p>\n

Nanobiotix<\/i><\/p>\n

Communications Department
\n<\/b><\/i>
Brandon Owens
\n<\/i>
VP, Communications
\n<\/i>
+1 (617) 852-4835
\n
contact@nanobiotix.com<\/span><\/a><\/p>\n

Investor Relations Department
\n<\/b>
Ricky Bhajun (EU)
\n<\/i>
Senior Manager, Investor Relations
\n<\/i>
+33 (0)1 79 97 29 99
\n
investors@nanobiotix.com<\/span><\/a><\/p>\n

M<\/span>edia Relations<\/i><\/p>\n

F<\/i>rance \u2013 Ulysse Communication
\n<\/b>
Pierre-Louis Germain
\n
+ 33 (0)6 64 79 97 51
\n
plgermain@ulysse-communication.com<\/a><\/p>\n

\nUS \u2013 Porter Novelli
\n<\/b>
Scott Stachowiak
\n<\/i>
+1 (212) 601 8000
\n
Scott.stachowiak@porternovelli.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts Europe United States North America France<\/p>\n

INDUSTRY KEYWORDS:<\/b> Pharmaceutical Health Oncology Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO \u2013 Nasdaq: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the closing of an additional 1,095,000 American Depositary Shares (\u201cADSs\u201d) pursuant to the full exercise of the underwriters\u2019 option to purchase additional ADSs in connection with the Company\u2019s initial public offering on the Nasdaq Global Select Market. The 1,095,000 additional ADSs were sold at $13.50 per ADS, the same public offering price as in the initial public offering. Consequently, the total number of ordinary shares issued amounts to 8,395,000, including 6,540,000 in the form of ADSs, and the total … <\/p>\n

Continue reading “Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403054","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO \u2013 Nasdaq: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the closing of an additional 1,095,000 American Depositary Shares (\u201cADSs\u201d) pursuant to the full exercise of the underwriters\u2019 option to purchase additional ADSs in connection with the Company\u2019s initial public offering on the Nasdaq Global Select Market. The 1,095,000 additional ADSs were sold at $13.50 per ADS, the same public offering price as in the initial public offering. Consequently, the total number of ordinary shares issued amounts to 8,395,000, including 6,540,000 in the form of ADSs, and the total … Continue reading "Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-18T21:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs\",\"datePublished\":\"2020-12-18T21:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/\"},\"wordCount\":883,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/\",\"name\":\"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-18T21:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/","og_locale":"en_US","og_type":"article","og_title":"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs - Market Newsdesk","og_description":"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO \u2013 Nasdaq: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the closing of an additional 1,095,000 American Depositary Shares (\u201cADSs\u201d) pursuant to the full exercise of the underwriters\u2019 option to purchase additional ADSs in connection with the Company\u2019s initial public offering on the Nasdaq Global Select Market. The 1,095,000 additional ADSs were sold at $13.50 per ADS, the same public offering price as in the initial public offering. Consequently, the total number of ordinary shares issued amounts to 8,395,000, including 6,540,000 in the form of ADSs, and the total … Continue reading \"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-18T21:03:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs","datePublished":"2020-12-18T21:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/"},"wordCount":883,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/","name":"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-18T21:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201218005508r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-closing-of-underwriters-option-to-purchase-additional-adss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nanobiotix Announces Closing of Underwriters\u2019 Option to Purchase Additional ADSs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403054"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403054\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}